CVS on XNYS, Retail, CVS HEALTH CORPORATION, job postings
Measures activity, not value. Not investment advice.
Shares fell 13% in one month while quarterly revenue rose 5.4% to $108.4B.
WatchCapital spending rose 17% last quarter to $817M
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
CVS Health currently offers a diverse set of healthcare services, although it plans to split into two organizations in early 2028. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 26 million medical members. The acquisition of Oak Street Health added primary care services to the mix.
Industry
Retail-drug stores and proprietary stores (Retail)
expected around 9 Feb 2027 (an estimate: a year ago it reported on 10 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $108.4B, net income $2.2B.
31 Dec 2021RevenueNet incomeNet losstallest bar $108.4B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$108.4B
$2.2B
30 Jun 2026
$106.1B
$3.0B
31 Mar 2026
$100.4B
$2.9B
31 Dec 2025
$105.7B
$2.9B
30 Sep 2025
$102.9B
-$4.0B
30 Jun 2025
$98.9B
$1.0B
31 Mar 2025
$94.6B
$1.8B
31 Dec 2024
$97.7B
–
30 Sep 2024
$95.4B
$87.0M
30 Jun 2024
$91.2B
$1.8B
31 Mar 2024
$88.4B
$1.1B
31 Dec 2023
$93.8B
–
30 Sep 2023
$89.8B
$2.3B
30 Jun 2023
$88.9B
$1.9B
31 Mar 2023
$85.3B
$2.1B
31 Dec 2022
$83.8B
$2.3B
30 Sep 2022
$81.2B
-$3.4B
30 Jun 2022
$80.6B
$3.0B
31 Mar 2022
$76.8B
$2.3B
31 Dec 2021
$76.6B
$1.3B
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$420.6B
$394.1B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+6.7%
+4.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$11.0B
$469.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$8.61
$0.38
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
44.2%
44.8%
37.9%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
3.6%
1.2%
4.1%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
2.6%
0.1%
2.7%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
14.4%
12.0%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$15.6B
$6.3B
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$14.9B
$11.2B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$60.7B
$65.8B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$45.8B
$54.6B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.75
0.45
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$62.91
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
9.4
19.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
0.25
0.58
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
0.35
0.89
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.3
2.3
Dividend yieldiDividends per share declared in the latest fiscal year divided by the share price.
3.3%
1.8%
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$2.0M
bought $2.0M, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-3.0%
1,968 13F filers vs 2,029
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
87%
1.1B shares held by 13F filers (30 Sep 2026) of 1.3B outstanding (28 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
1.4%
17.9M shares sold short (30 Oct 2026) of 1.3B outstanding (28 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
2.8
17.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+10%
16.2M shares sold short in the report before, 17.9M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
24%
24% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 39%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+5.4%
$108.4B vs $102.9B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+17%
$817.0M vs $698.0M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$4.5M
the 12 months before: $1.3M
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$12.8M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
59
59 articles in the last 7 days; its usual week has 8 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
7.4×
59 articles in the last 7 days; its usual week has 8.
Price $80.84 on 20 Nov 2026, +6.3% over 12 months (12-month range $70.08 to $110.60)
Sharp change
8-K and other filings
WARN layoff notice
Lobbying filing
Insider net buying (open market). Insiders sold a net $321.7M in the last 12 months (the 12 months before: -$252.6M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 408 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $108.4B in the latest quarter, +5.4% on a year earlier.Capital spending per quarter. Capital spending $817.0M in the latest quarter, +17% on a year earlier.Institutional holders (13F filers). 1,968 13F filers reported holding it in the latest 13F quarter, +13% on a year earlier.Federal obligations. Federal obligations: $6.2M published in the last 12 months, -7.6% on the 12 months before.Lobbying spend. Lobbying spend: $12.8M published in the last 12 months, +19% on the 12 months before.Workers in WARN layoff notices. Workers in WARN layoff notices: 61 published in the last 12 months, -84% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.
Quarter ended 31 Dec 2021: $76.6B, +10% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $76.8B, +11% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $80.6B, +11% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $81.2B, +10% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $83.8B, +9.5% on a year earlier; public on 9 Feb 2023
Quarter ended 31 Mar 2023: $85.3B, +11% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $88.9B, +10% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $89.8B, +11% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $93.8B, +12% on a year earlier; public on 8 Feb 2024
Quarter ended 31 Mar 2024: $88.4B, +3.7% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $91.2B, +2.6% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $95.4B, +6.3% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $97.7B, +4.2% on a year earlier; public on 13 Feb 2025
Quarter ended 31 Mar 2025: $94.6B, +7.0% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $98.9B, +8.4% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $102.9B, +7.8% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $105.7B, +8.2% on a year earlier; public on 11 Feb 2026
Quarter ended 31 Mar 2026: $100.4B, +6.2% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $106.1B, +7.3% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $108.4B, +5.4% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $597.0M, -16% on a year earlier; public on 10 Feb 2022
Quarter ended 31 Mar 2022: $1.1B, +27% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $408.0M, -16% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $580.0M, -4.6% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $688.0M, +15% on a year earlier; public on 9 Feb 2023
Quarter ended 31 Mar 2023: $984.0M, -6.4% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $591.0M, +45% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $545.0M, -6.0% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $911.0M, +32% on a year earlier; public on 8 Feb 2024
Quarter ended 31 Mar 2024: $705.0M, -28% on a year earlier; public on 2 May 2024
Quarter ended 30 Jun 2024: $638.0M, +8.0% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $670.0M, +23% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $768.0M, -16% on a year earlier; public on 13 Feb 2025
Quarter ended 31 Mar 2025: $743.0M, +5.4% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $607.0M, -4.9% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $698.0M, +4.2% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $784.0M, +2.1% on a year earlier; public on 11 Feb 2026
Quarter ended 31 Mar 2026: $849.0M, +14% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $691.0M, +14% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $817.0M, +17% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 2,073; public on 14 Feb 2022
31 Mar 2022 report: 2,199; public on 16 May 2022
30 Jun 2022 report: 2,163; public on 15 Aug 2022
30 Sep 2022 report: 2,128; public on 14 Nov 2022
31 Dec 2022 report: 2,181; public on 14 Feb 2023
31 Mar 2023 report: 2,102; public on 15 May 2023
30 Jun 2023 report: 2,012; public on 14 Aug 2023
30 Sep 2023 report: 1,929; public on 14 Nov 2023
31 Dec 2023 report: 2,081; public on 14 Feb 2024
31 Mar 2024 report: 2,040; public on 15 May 2024
30 Jun 2024 report: 1,795; public on 14 Aug 2024
30 Sep 2024 report: 1,727; public on 14 Nov 2024
31 Dec 2024 report: 1,566; public on 14 Feb 2025
31 Mar 2025 report: 1,665; public on 15 May 2025
30 Jun 2025 report: 1,673; public on 14 Aug 2025
30 Sep 2025 report: 1,747; public on 14 Nov 2025
31 Dec 2025 report: 1,847; public on 17 Feb 2026
31 Mar 2026 report: 1,816; public on 15 May 2026
30 Jun 2026 report: 2,029; public on 14 Aug 2026
30 Sep 2026 report: 1,968; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: -$84K published
Month from 1 Jan 2022: $159.6M published
Month from 1 Feb 2022: $34K published
Month from 1 Mar 2022: -$27.8M published
Month from 1 Apr 2022: $14K published
Month from 1 May 2022: $14K published
Month from 1 Jun 2022: $122.8M published
Month from 1 Jul 2022: $14K published
Month from 1 Aug 2022: $5.8M published
Month from 1 Sep 2022: $2.8M published
Month from 1 Oct 2022: $512K published
Month from 1 Nov 2022: $155K published
Month from 1 Dec 2022: $14K published
Month from 1 Jan 2023: $14K published
Month from 1 Feb 2023: -$696K published
Month from 1 Mar 2023: $1.2M published
Month from 1 May 2023: $6.7M published
Month from 1 Jun 2023: -$711K published
Month from 1 Jul 2023: -$7K published
Month from 1 Aug 2023: $30K published
Month from 1 Sep 2023: $123.4M published
Month from 1 Oct 2023: $270K published
Month from 1 Nov 2023: $0 published
Month from 1 Dec 2023: $65K published
Month from 1 Jan 2024: $20.0M published
Month from 1 Feb 2024: $29K published
Month from 1 Jun 2024: $0 published
Month from 1 Aug 2024: -$142K published
Month from 1 Dec 2024: $0 published
Month from 1 May 2025: $1.4M published
Month from 1 Jun 2025: $0 published
Month from 1 Jul 2025: $11K published
Month from 1 Sep 2025: $200K published
Month from 1 Oct 2025: $5.1M published
Month from 1 Apr 2026: $204K published
Month from 1 Jun 2026: -$4K published
Month from 1 Jul 2026: -$1.0M published
Month from 1 Aug 2026: $0 published
Month from 1 Sep 2026: $48K published
Month from 1 Oct 2026: $7.0M published
Lobbying spend
Quarter from 1 Jan 2022: $3.6M published
Quarter from 1 Apr 2022: $4.7M published
Quarter from 1 Jul 2022: $2.5M published
Quarter from 1 Oct 2022: $2.7M published
Quarter from 1 Jan 2023: $4.8M published
Quarter from 1 Apr 2023: $7.8M published
Quarter from 1 Jul 2023: $2.2M published
Quarter from 1 Oct 2023: $1.9M published
Quarter from 1 Jan 2024: $2.1M published
Quarter from 1 Apr 2024: $3.5M published
Quarter from 1 Jul 2024: $2.7M published
Quarter from 1 Oct 2024: $1.7M published
Quarter from 1 Jan 2025: $2.3M published
Quarter from 1 Apr 2025: $3.7M published
Quarter from 1 Jul 2025: $2.2M published
Quarter from 1 Oct 2025: $2.5M published
Quarter from 1 Jan 2026: $2.6M published
Quarter from 1 Apr 2026: $3.7M published
Quarter from 1 Jul 2026: $4.0M published
Quarter from 1 Oct 2026: $2.5M published
Workers in WARN layoff notices
Month from 1 Aug 2023: 471 published
Month from 1 Sep 2023: 207 published
Month from 1 Oct 2023: 1 published
Month from 1 Nov 2023: 90 published
Month from 1 Oct 2024: 111 published
Month from 1 Mar 2025: 3 published
Month from 1 Aug 2025: 157 published
Month from 1 Nov 2025: 219 published
Month from 1 Dec 2025: 61 published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $2.0M (6 Nov 2026), 3,106× its normal reading; higher than 99% of its own history.
Department of Health and Human ServicesFood and Drug Administration
$5.5M
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) REQUIREMENT FOR BIOLOGICS EFFECTIVENESS AND SAFETY (BEST) INITIATIVE #3: HEALTH CARE DATA SOURCES FOR SURVEILLANCE OF BIOLOGICS (BEST 3)
Department of Health and Human ServicesFood and Drug Administration
$1.4M
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) REQUIREMENT FOR BIOLOGICS EFFECTIVENESS AND SAFETY (BEST) INITIATIVE #3: HEALTH CARE DATA SOURCES FOR SURVEILLANCE OF BIOLOGICS (BEST 3)
Reported lobbying spend: $2.5M in Q3 2026, $4.0M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
9 Mar 2026
New
Michael Best Strategies LLCfor CVS Health
Issues related to retail pharmacies, insurance, and Medicare/Medicaid.Health issues, Pharmacy, Medicare/Medicaid, Insurance
Issues related to drug pricing Issues related to health reform proposals Issues related to representation in COVID-19-related packages HR 1770 - Equitable Community Access to Pharmacist Services Act Issues related to Pharmacy Benefit Managers; Issues related to hospital payments Issues related to hospital inclusion and representation in COVID-19 packages; HR 1770 Public Law Number 116-136 CARES Act H.R. 1868 An Act to prevent across-the-board direct spending cuts, and for other purposesPharmacy, Budget
Two or more unrelated kinds of records unusual within 30 days
6 Feb 2024confirmed
Confirmed across sources Government contracts and Short interest and volume
CVS Health(CVS): booked $20.0M in federal contract and grant obligations in January 2024, 129× its normal month, while it had 30.8M shares sold short in the 15 Feb 2024 report, 2.1× the same report last year. Two unrelated kinds of activity within 42 days.
Short interest and volume: Short interest spike, became public on 25 Jan 2024
Government contracts: Federal obligations jump, became public on 18 Jan 2024
Short interest and volume: Short interest spike, became public on 10 Feb 2024
Short interest and volume: Short interest spike, became public on 28 Feb 2024
Short interest and volume: Short interest spike, became public on 12 Mar 2024
January 2024 against the 5 months before it.
this monthearliernormal: $155KSee the evidence (5 changes)
Short interest and volume: Short interest spike became public on 25 Jan 2024
CVS Health had 42.5M shares sold short in the 12 Jan 2024 report, 1.7× the same report last year.
This period
42.5M (the 12 Jan 2024 report)
Normal report (median of 24 earlier)
15.7M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+17.1
Same report last year
25.3M
History used
2,205 days
the 12 Jan 2024 report24 earlier reportsnormal: 15.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Government contracts: Federal obligations jump became public on 18 Jan 2024
CVS Health booked $20.0M in federal contract and grant obligations in January 2024, 129× its normal month.
This period
$20.0M (January 2024)
Normal month (median of 5 earlier)
$155K
Typical spread (median absolute deviation)
$852K
How far from its usual level
+15.7
Same month last year
-$697K
History used
5,966 days
January 20245 earlier monthsnormal: $155K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 10 Feb 2024
CVS Health had 36.8M shares sold short in the 31 Jan 2024 report, 1.8× the same report last year.
This period
36.8M (the 31 Jan 2024 report)
Normal report (median of 24 earlier)
15.7M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+13.4
Same report last year
20.6M
History used
2,224 days
the 31 Jan 2024 report24 earlier reportsnormal: 15.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Feb 2024
CVS Health had 30.8M shares sold short in the 15 Feb 2024 report, 2.1× the same report last year.
This period
30.8M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
15.7M
Typical spread (median absolute deviation)
1.0M
How far from its usual level
+9.6
Same report last year
14.7M
History used
2,239 days
the 15 Feb 2024 report24 earlier reportsnormal: 15.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Mar 2024
CVS Health had 24.2M shares sold short in the 29 Feb 2024 report, 1.6× the same report last year.
This period
24.2M (the 29 Feb 2024 report)
Normal report (median of 24 earlier)
15.9M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+4.8
Same report last year
14.7M
History used
2,253 days
the 29 Feb 2024 report24 earlier reportsnormal: 15.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
27 Oct 2023confirmed
Confirmed across sources Government contracts and Layoff notices
CVS Health(CVS): booked $123.4M in federal contract and grant obligations in September 2023, 38× the same month last year, while it filed a WARN layoff notice covering 1 workers within 30 days (Wellesley, MA). Two unrelated kinds of activity within 16 days.
Government contracts: Federal obligations jump, became public on 26 Sep 2023
Layoff notices: WARN layoff notice, became public on 27 Oct 2023
September 2023 against the 5 months before it.
this monthearliernormal: $3.3MSee the evidence (2 changes)
Government contracts: Federal obligations jump became public on 26 Sep 2023
CVS Health booked $123.4M in federal contract and grant obligations in September 2023, 38× the same month last year.
This period
$123.4M (September 2023)
Normal month (median of 5 earlier)
$3.3M
Typical spread (median absolute deviation)
$3.3M
How far from its usual level
+24.8
Same month last year
$3.3M
History used
5,843 days
September 20235 earlier monthsnormal: $3.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.
Fires on a WARN notice after 30 days without one; notices within 30 days are summed.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
31 Jan 2023confirmed
Confirmed across sources Lobbying and Short interest and volume
CVS Health(CVS): reported $4.8M of lobbying spend for the quarter ended 31 Dec 2022, 1.3× the same quarter last year, while it had 25.3M shares sold short in the 13 Jan 2023 report, 1.5× the same report last year. Two unrelated kinds of activity within 21 days.
Lobbying: Lobbying spend jump, became public on 6 Jan 2023
Short interest and volume: Short interest spike, became public on 26 Jan 2023
Short interest and volume: Short interest spike, became public on 10 Feb 2023
The quarter ended 31 Dec 2022 against the 8 quarters before it.
this quarterearliernormal: $3.1MSee the evidence (3 changes)
Lobbying: Lobbying spend jump became public on 6 Jan 2023
CVS Health reported $4.8M of lobbying spend for the quarter ended 31 Dec 2022, 1.3× the same quarter last year.
This period
$4.8M (the quarter ended 31 Dec 2022)
Normal quarter (median of 8 earlier)
$3.1M
Typical spread (median absolute deviation)
$310K
How far from its usual level
+3.6
Same quarter last year
$3.6M
History used
4,748 days
the quarter ended 31 Dec 20228 earlier quartersnormal: $3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Short interest and volume: Short interest spike became public on 26 Jan 2023
CVS Health had 25.3M shares sold short in the 13 Jan 2023 report, 1.5× the same report last year.
This period
25.3M (the 13 Jan 2023 report)
Normal report (median of 24 earlier)
13.9M
Typical spread (median absolute deviation)
744K
How far from its usual level
+8.2
Same report last year
17.0M
History used
1,841 days
the 13 Jan 2023 report24 earlier reportsnormal: 13.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Feb 2023
CVS Health had 20.6M shares sold short in the 31 Jan 2023 report, 1.4× the same report last year.
This period
20.6M (the 31 Jan 2023 report)
Normal report (median of 24 earlier)
13.9M
Typical spread (median absolute deviation)
744K
How far from its usual level
+4.8
Same report last year
14.4M
History used
1,859 days
the 31 Jan 2023 report24 earlier reportsnormal: 13.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
drew 5,359 Wikipedia page views in the week of 26 Jan 2026, 1.1× the same week last year.
Same week last year: 4,741; its normal week is 3,356.
See the evidence
This period
5,359 (the week of 26 Jan 2026)
Normal week (median of 26 earlier)
3,356
Typical spread (median absolute deviation)
252
How far from its usual level
+5.4
Same week last year
4,741
History used
2,588 days
the week of 26 Jan 202626 earlier weeksnormal: 3,356
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
saw 235 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year.
Same quarter last year: 85; its normal quarter is 92.5.
See the evidence
This period
235 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
92.5
Typical spread (median absolute deviation)
13.5
How far from its usual level
+7.1
Same quarter last year
85
History used
4,200 days
the quarter ended 31 Mar 20258 earlier quartersnormal: 92.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
drew 12K Wikipedia page views in the week of 2 Dec 2024, 2.2× the same week last year.
Same week last year: 5,335; its normal week is 5,598.
See the evidence
This period
12K (the week of 2 Dec 2024)
Normal week (median of 26 earlier)
5,598
Typical spread (median absolute deviation)
378
How far from its usual level
+10.9
Same week last year
5,335
History used
2,168 days
the week of 2 Dec 202426 earlier weeksnormal: 5,598
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Fires on an 8-K with item 5.02 after 90 days without one.
Showing the newest 40 of 180 entries; narrow the window or the kind of data to see older ones.
Not listed: 258 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000064803
Ticker
CVS
Domain
cvshealth.com
Employer name
caremark, aetna international, Aetna Medicaid Administrators LLC, aetna resources and 10 more (13 unverified)
Fein
05-0340626, 05-0501917, 45-5532056, 46-2605165 and 3 more (7 unverified)
Hq location
RI|WOONSOCKET|02895 (1 unverified)
Lobbying client
cvs, cvs caremark, cvs health, cvs health and subsidiaries and 8 more
Name
Accendo Insurance Company, Accordant Health Services, L.L.C., ACS ACQCO CORP., Active Health Management, Inc. and 451 more
Uei
ZK27LU473Y27
Wikidata
Q624375
Wikipedia
CVS Health
DOL H-1B labor condition applications and PERM certifications131 data points22 Nov 2021 to 28 Sep 2026
Federal lobbying disclosures (LDA)81 records, 275 data points30 Dec 1899 to 30 Sep 2026
SEC Form 13F institutional holdings22 records, 481 data points30 Jun 2013 to 10 Nov 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)198 records9 Feb 2016 to 4 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1286 data points30 Dec 2006 to 28 Oct 2026
SEC Form 4 insider transactions113 records, 380 data points5 Jan 2016 to 6 Nov 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards12 records, 3591 data points1 Oct 2007 to 25 Sep 2026
WARN layoff notices (state labor agencies)17 records, 39 data points15 Apr 1996 to 7 Nov 2025
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026